The latest move is a key step for an Alamo City company pursuing widespread adoption of its core technology.
As published in the San Antonio Business Journal
By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal
Nov. 6, 2023
San Antonio-based bioAffinity Technologies has taken another key step in the commercialization of its novel cancer detection platform, securing a national sales director to lead that effort.
Dallas Coleman brings more than 15 years of experience in medical sales and marketing to the team as the Alamo City biotech firm seeks to move its CyPath Lung early-stage cancer detection technology to market.
“Hiring Dallas is another key milestone in the commercialization of CyPath Lung,” bioAffinity CEO Maria Zannes told me, noting that the company’s newest hire will fine-tune its overall market strategy.
Coleman was most recently an executive account manager for Pennsylvania-based Olympus America in its therapeutic division. He was an integral part of that company’s product launch team, engaging with surgeons and physicians working with patients dealing with lung disease.
“We expect the relationships he has built can provide a pathway to raise physician awareness of CyPath Lung,” Zannes said.
Coleman will report to Zannes and lead the company’s CyPath Lung marketing group. One of his chief roles will be to identify new business opportunities for the San Antonio biotech and its core technology.
Coleman’s résumé also includes work with Caldera Medical, a medical device company focused on women’s health, and Ecolab, a global sustainability corporation focused on water safety.
“My career has consistently revolved around extending the lives of patients and improving their quality of life,” Coleman said. “More than 14 million Americans are at high risk for lung cancer, and the opportunity to share CyPath Lung with their care teams is highly motivating.”
The hiring of Coleman comes after bioAffinity (Nasdaq: BIAF) crossed a critical barrier in October, securing key reimbursement approval for its technology that’s expected to bolster market opportunities.
“His experience and demonstrated track record in building strong relationships with our target customers and creating effective sales organizations is a timely and strategic fit as we ramp up the commercialization of CyPath Lung,” Zannes said.